Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510016 · ClinicalTrials.gov registry record · Phase 2
Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
A Phase 2 study of Neonatal Abstinence Syndrome, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00510016 is a Phase 2 study of Neonatal Abstinence Syndrome that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 80 participants, above the 62-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00510016, a Phase 2 study of Neonatal Abstinence Syndrome, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.
Conditions Studied
Interventions
- DRUG Clonidine HCL
Study Locations (1)
Maryland
- Johns Hopkins Medical Institutions - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510016
The ClinicalTrials.gov registry entry for NCT00510016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (29% higher). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neonatal Abstinence Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Clonidine HCL is the first listed.
NCT00510016 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00510016 about?
NCT00510016 is a clinical study titled "Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome". To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.
What is the current status of trial NCT00510016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2002-07. Estimated completion is 2005-12.
What conditions does trial NCT00510016 study?
This clinical trial studies the following conditions: Neonatal Abstinence Syndrome.
What interventions are being tested in trial NCT00510016?
The interventions under investigation include: Clonidine HCL (DRUG).
Who is sponsoring clinical trial NCT00510016?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00510016 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neonatal Abstinence Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants
COMPLETED · Phase 2
-
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
RECRUITING · NA
-
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
RECRUITING
-
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
ACTIVE NOT RECRUITING · NA
-
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
ACTIVE NOT RECRUITING · NA
-
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.